Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO 2/ENGOT Ov-21 trial

被引：18
|
作者：
Frenel, J-S. [1 ,2 ]
Kim, J-W. [3 ]
Berton-Rigaud, D. [1 ,2 ]
Asher, R. [4 ]
Vidal, L. [5 ,6 ]
Pautier, P. [7 ,8 ]
Ledermann, J. A. [9 ,10 ]
Penson, R. T. [11 ]
Oza, A. M. [12 ]
Korach, J. [13 ,14 ]
Huzarski, T. [15 ]
Pignata, S. [16 ,17 ]
Colombo, N. [18 ,19 ,20 ]
Park-Simon, T-W. [21 ,22 ]
Tamura, K. [23 ]
Sonke, G. S. [24 ,25 ]
Freimund, A. [26 ]
Lee, C. K. [27 ]
Pujade-Lauraine, E. [28 ]
机构：
[1] GINECO, Ctr Rene Gauducheau, St Herblain, France
[2] Inst Cancerol Ouest, St Herblain, France
[3] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
[4] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] GEICO, Med Oncol, Barcelona, Spain
[6] H Clin Barcelona, Barcelona, Spain
[7] GINECO, Med Oncol, Villejuif, France
[8] Gustave Roussy Canc Ctr, Villejuif, France
[9] NCRI, Dept Oncol, London, England
[10] UCL, London, England
[11] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA
[12] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[13] ISGO, Dept Gynecol Oncol, Tel Aviv, Israel
[14] Chaim Sheba Med Ctr, Tel Aviv, Israel
[15] Pomeranian Med Univ, Int Hereditary Canc Ctr, Genet & Pathol, Szczecin, Poland
[16] MITO, Dept Urol & Gynecol, Naples, Italy
[17] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[18] MaNGO, Gynecol Oncol Dept, Milan, Italy
[19] European Inst Oncol, Milan, Italy
[20] Univ Milano Bicocca, Milan, Italy
[21] AGO, Gynecol Oncol, Hannover, Germany
[22] Hannover Med Sch, Hannover, Germany
[23] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[24] DGOG, Dept Med Oncol, Amsterdam, Netherlands
[25] Netherlands Canc Inst, Amsterdam, Netherlands
[26] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[27] St George Publ Hosp, Canc Care Ctr, Sydney, NSW, Australia
[28] ARCAGY GINECO, Med Oncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.952
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
813MO
引用
收藏
页码：S615 / S615
页数：1
相关论文
共 50 条
  • [1] Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).
    Frenel, Jean-Sebastien
    Kim, Jae-Weon
    Berton, Dominique
    Asher, Rebecca
    Vidal, Laura
    Pautier, Patricia
    Ledermann, Jonathan A.
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lowe, Elizabeth S.
    Freimund, Alison E.
    Lee, Chee Khoon
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
    Frenel, J. S.
    Kim, J. W.
    Aryal, N.
    Asher, R.
    Berton, D.
    Vidal, L.
    Pautier, P.
    Ledermann, J. A.
    Penson, R. T.
    Oza, A. M.
    Korach, J.
    Huzarski, T.
    Pignata, S.
    Colombo, N.
    Park-Simon, T. W.
    Tamura, K.
    Sonke, G. S.
    Freimund, A. E.
    Lee, C. K.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2022, 33 (10) : 1021 - 1028
  • [3] Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
    Trillsch, Fabian
    Mahner, Sven
    Ataseven, Beyhan
    Asher, Rebecca
    Aryal, Nanda
    Dubot, Coraline
    Clamp, Andrew
    Penson, Richard T.
    Oza, Amit
    Amit, Amnon
    Huzarski, Tomasz
    Casado, Antonio
    Scambia, Giovanni
    Friedlander, Michael
    Colombo, Nicoletta
    Fujiwara, Keiichi
    Sonke, Gabe S.
    Denys, Hannelore
    Lowe, Elizabeth S.
    Lee, Chee K.
    Pujade-Lauraine, Eric
    GYNECOLOGIC ONCOLOGY, 2022, 165 (01) : 40 - 48
  • [4] Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)
    Penson, R.
    Kaminsky-Forrett, M-C.
    Ledermann, J.
    Brown, C.
    Plante, M.
    Korach, J.
    Huzarski, T.
    Lista, A. Gomez de Liano
    Pisano, C.
    Friedlander, M.
    Colombo, N.
    Gropp-Meier, M.
    Nakai, H.
    Sonke, G. S.
    Kim, J-W.
    Vergote, I.
    Allen, A.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)
    Oza, A. M.
    Combe, P.
    Ledermann, J.
    Marschner, S.
    Amit, A.
    Huzarski, T.
    Lainez Milagro, N.
    Savarese, A.
    Scott, C.
    Nicoletto, M. O.
    Harter, P.
    Enomoto, T.
    Sonke, G. S.
    Kim, J-W.
    Vergote, I.
    Allen, A.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
    Friedlander, Michael
    Gebski, Val
    Gibbs, Emma
    Davies, Lucy
    Bloomfield, Ralph
    Hilpert, Felix
    Wenzel, Lari B.
    Eek, Daniel
    Rodrigues, Manuel
    Clamp, Andrew
    Penson, Richard T.
    Provencher, Diane
    Korach, Jacob
    Huzarski, Tomasz
    Vidal, Laura
    Salutari, Vanda
    Scott, Clare
    Nicoletto, Maria Ornella
    Tamura, Kenji
    Espinoza, David
    Joly, Florence
    Pujade-Lauraine, Eric
    LANCET ONCOLOGY, 2018, 19 (08): : 1126 - 1134
  • [7] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
    Pujade-Lauraine, Eric
    Ledermann, Jonathan A.
    Selle, Frederic
    Gebski, Val
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Poveda, Andres
    Pignata, Sandro
    Friedlander, Michael
    Colombo, Nicoletta
    Harter, Philipp
    Fujiwara, Keiichi
    Ray-Coquard, Isabelle
    Banerjee, Susana
    Liu, Joyce
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Pautier, Patricia
    LANCET ONCOLOGY, 2017, 18 (09): : 1274 - 1284
  • [8] Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.
    Trillsch, Fahian
    Mahner, Sven
    Ataseven, Beyhan
    Asher, Rebecca
    Dubot, Coraline
    Clamp, Andrew R.
    Peson, Richard T.
    Oza, Amit M.
    Amit, Amnon
    Huzarski, Tomasz
    Casado, Antonio
    Scambia, Giovanni
    Friedlander, Michael
    Colombo, Nicoletta
    Fujiwara, Keiichi
    Sonke, Gabe S.
    Denys, Hannelore
    Lowe, Elizabeth S.
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
    Francis, K. E.
    Kim, S., I
    Friedlander, M.
    Gebski, V
    Ray-Coquard, I
    Clamp, A.
    Penson, R. T.
    Oza, A.
    Perri, T.
    Huzarski, T.
    Martin-Lorente, C.
    Cecere, S. C.
    Colombo, N.
    Ataseven, B.
    Fujiwara, K.
    Sonke, G.
    Vergote, I
    Pujade-Lauraine, E.
    Kim, J-W
    Lee, C. K.
    ANNALS OF ONCOLOGY, 2022, 33 (06) : 593 - 601
  • [10] REAL WORLD OUTCOMES OF OLAPARIB MAINTENANCE THERAPY IN PATIENTS WITH BRCA1/2-MUTATED PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER
    McLaren, A.
    White, M.
    Cartwright, D.
    Brown, J.
    Randhawa, M.
    Roxburgh, T.
    Glasspool, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A166 - A166
12345